Evidence map›Paper›PMID 37021342›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2023

Dynamic changes in nocturnal heart rate predict short-term cardiovascular events in patients using the wearable cardioverter-defibrillator: from the WEARIT-France cohort study.

Rodrigue Garcia, Peder Emil Warming, Kumar Narayanan, Pascal Defaye, Laurence Guedon-Moreau, Hugues Blangy, Olivier Piot, Christophe Leclercq, Eloi Marijon, WEARIT-France Investigators

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03319160 (Post-market Clinical Follow-up Study Evaluating the Efficacy and Safety of LifeVest in Real-life Settings in France), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03319160 completednot on this map

Post-market Clinical Follow-up Study Evaluating the Efficacy and Safety of LifeVest in Real-life Settings in France

Typeobservational_patient_registrySponsorZoll Medical CorporationRan2017 to 2019Enrolled1,164ConditionsSudden Cardiac Death, Left Ventricular Dysfunction, Cardiac Event, Cardiac ArrythmiasArmsWearable Cardioverter Defibrillator
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Observational
  5. A review on wearable cardioverter-defibrillators in clinical practice for sudden cardiac death prevention and heart failure management.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Risk stratification of sudden cardiac death: a review.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Rodrigue GarciaDepartment of Cardiology, University Hospital of Poitiers, 86021 Poitiers, France.ORCID 0000-0001-9350-2437
Peder Emil WarmingDepartment of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark.ORCID 0000-0003-0508-2503
Kumar NarayananDepartment of Cardiology, Medicover Hospitals, Hyderabad, Telangana 500081, India.ORCID 0000-0003-4897-240X
Pascal DefayeDepartment of Cardiology, University Hospital Grenoble Alpes, Grenoble 38043, France.ORCID 0000-0002-7183-4278
Laurence Guedon-MoreauHeart and Lung Institute, University Hospital of Lille, Lille 59000, France.
Hugues BlangyDepartment of Cardiology, University Hospital of Nancy, Vandoeuvre-Lès-Nancy 54500, France.
Olivier PiotDepartment of Cardiology, Cardiology Center of Nord, Saint Denis 93200, France.ORCID 0000-0002-6311-4983
Christophe LeclercqDepartment of Cardiology, University Hospital Pontchaillou, Rennes 35000, France.ORCID 0000-0002-4399-5568
Eloi MarijonDepartment of Cardiology, European Georges Pompidou Hospital, Paris Cedex 15, 75908, France.ORCID 0000-0001-7227-3428
WEARIT-France Investigators
Inserm · FRCentre Cardiologique du Nord · FRCentre Hospitalier Régional et Universitaire de Nancy · FRHôpital Pontchaillou · FRCentre Hospitalier Universitaire de Grenoble · FRCopenhagen University Hospital · DKLille’s Cardiology Hospital · FRUniversité de Poitiers · FR

Funding

Institut National de la Santé et de la Recherche MédicaleZOLL company
6 · The paper itself

Abstract

aimsWhile elevated resting heart rate measured at a single point of time has been associated with cardiovascular outcomes, utility of continuous monitoring of nocturnal heart rate (NHR) has never been evaluated. We hypothesized that dynamic NHR changes may predict, at short term, impending cardiovascular events in patients equipped with a wearable cardioverter-defibrillator (WCD). METHODS AND

resultsThe WEARIT-France prospective cohort study enrolled heart failure patients with WCD between 2014 and 2018. Night-time was defined as midnight to 7 a.m. NHR initial trajectories were classified into four categories based on mean NHR in the first week (High/Low) and NHR evolution over the second week (Up/Down) of WCD use. The primary endpoint was a composite of cardiovascular death and heart failure hospitalization. A total of 1013 [61 (interquartile range, IQR 53-68) years, 16% women, left ventricular ejection fraction 26% (IQR 22-30)] were included. During a median WCD wear duration of 68 (IQR 44-90) days, 58 patients (6%) experienced 69 events. After considering potential confounders, High-Up NHR trajectory was significantly associated with the primary endpoint compared to Low-Down [adjusted hazard ratio (HR) 6.08, 95% confidence interval (CI) 2.56-14.45, P < 0.001]. Additionally, a rise of >5 bpm in weekly average NHR from the preceding week was associated with 2.5 higher composite event risk (HR 2.51, 95% CI 1.22-5.18, P = 0.012) as well as total mortality (HR 11.21, 95% CI 3.55-35.37, P < 0.001) and cardiovascular hospitalization (HR 2.70, 95% CI 1.51-4.82, P < 0.001).

conclusionDynamic monitoring of NHR may allow timely identification of impending cardiovascular events, with the potential for 'pre-emptive' action. REGISTRATION NUMBER: Clinical Trials.gov Identifier: NCT03319160.

Indexed as

Heart FailureWearable Electronic DevicesCohort StudiesDefibrillatorsFemaleHeart RateHumansMaleProspective StudiesStroke VolumeVentricular Function, LeftHeart failureHeart ratePre-emptive actionRemote monitoringWearable cardioverter-defibrillator

Identifiers

PMID37021342
PMCPMC10227653
OpenAlexW4362658109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.